Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Nov 9 2016

Full Issue

Pharma Gets Reprieve From 'Worst-Case Scenario,' But Trump Is Still A Question Mark

The pharmaceutical industry was braced for a possible Democratic takeover. But Donald Trump might not be an ally. Meanwhile, pharmaceutical stocks are up on the news of his win.

Stat: Big Pharma's Big Question: Is Trump Friend Or Foe?

Should President Donald Trump make drug makers relieved? Or anxious? They’re not sure. (Scott, 11/9)

The Wall Street Journal: Health-Care Stocks Emerge As Winners From Trump Vote

Health-care companies have emerged as the main gainers from Donald Trump’s win in the U.S. presidential election, despite a broad stock market selloff across the world. The U.S. premarket pointed to a 2% opening loss for the S&P 500 during early European trade, but futures on pharmaceuticals showed sharp rises, led by Endo International PLC, Mylan NV and Perrigo Co. PLC. The Stoxx Europe 600 index was down 0.5%, but the health-care and mining sectors notched 3.5% and 3% gains respectively. All other sectors were in the red. (Sindreu and Iosebashvili, 11/9)

Bloomberg: Drugmakers Jump As Republicans’ Victory Eases Regulatory Concern 

Health-care stocks surged in European and Asian trading as Republicans’ sweeping victory in the U.S. elections eased concerns that Democrats would require broader regulation and controls on drug prices in the world’s largest market for prescription drugs. Roche Holding AG, the world’s biggest maker of cancer drugs, gained 3 percent in Zurich, while France’s Sanofi climbed 2.8 percent in Paris. The Bloomberg EMEA Pharmaceutical Index jumped 3.7 percent, the most in almost two years, even as the the broader market slumped. Indian generic drugmakers, who sell to the U.S., also climbed. (Krege and Cordeiro, 11/8)

Meanwhile, the industry helped Sen. Richard Burr defeat his opponent —

Stat: The Drug Industry Sees A Key Ally In The Senate Prevail

A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry. North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross. (Kaplan, 11/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF